Following the increasing interest in access to investigational medicines from patients, the harmonization of guidance and research on the value of expanded access programs witnesses a critical rise.

Back in Boston as the only industry forum defining global regulations for EAP and your definitive networking opportunity to connect with managed access teams from other leading and new companies that are immersing themselves in this evolving field of opportunity and life-changing support.

Reunite with 120+ industry experts setting up and leading EAPs at the 4th Operationalize Expanded Access Programs Summit and gain practical take aways on how to construct a reliable system, define a clear exit strategy, understand updated local and global regulations, and determine the role of real-world data to optimize the operationalization of your EAP. This is your one-stop shop to capturing industry’s latest case studies in setting up a program globally, reaching physicians and patients, collecting real-world data, and maximizing vendor selection to improve the operationalization of EAP and streamline access to life-changing therapies.

What’s New for 2024?

• A deep dive into the country-level challenges and regulators’ requirements along with the best practices for labelling, shipping, and reporting to deliver a successful project across the US, LATAM and Middle East with UCB, GSK, Novartis, Biogen, Sanofi, SpringWorks Therapeutics and Day One Biopharmaceuticals
• A delve into the experiences and perspectives of physicians to better understand their pain points and how they become aware of EAPs to strengthen these relationships and move the field forward with the University of Michigan and Riboscience
• An active discussion into the role of real-world data and the setup of an EAP through value-based organisations to obtain a large community of patients and carry this out with ease with AstraZeneca

Don’t miss out on your opportunity to be amongst physicians, patients and passionate EAP and clinical supply experts from Novartis, Daiichi Sankyo, GSK, AstraZeneca, Gilead, Biogen, Sanofi, Eli Lilly, Regeneron, and many more to discover novel strategies in overcoming operational hurdles and deliver life-saving treatments to patients more efficiently.

To know more visit: https://operationalize-eap.com/